3 min read

Abveris beer: Get It While It's cold!

By Ryan Kelly on 6/30/20 8:59 AM

Made by mAb scientists, for mAb scientists
BEST ENJOYED AFTER A LONG DAY IN THE LAB

We teamed up with our neighbors at Castle Island Brewery to bring you specialty beers that mAb scientists are sure to love! Introducing mAb Scientist IPA and Six Pack mAbs Lager. Our team designed some hilarious labels and the Castle Island team came through with some delicious lager and IPA options. 

We'll be sending out cases of beer to our partners, but we also recognize many of you are working from home right now. Click below to provide your address information for us to send you some free brews! 

BEER CALL: ADD ME TO THE LIST!

mAb Scientist IPA: OUR FLAGSHIP BEER
Abveris Beer Labels FINAL 2020-04-072 mab scientist

This beer is smooth but punchy; balanced yet intense. Despite the colossal amount of hops crammed into this beer, it’s still remarkably approachable for pros and rookies alike!

Our team held a naming competition for our flagship beer. After a close vote with many great names in the running, mAbScientist IPA rose to victory.  You may be asking: why does she have antibodies for hands? Fun fact: our monthly all-hands meeting is called "Monthly mAbs For Hands" after our all hands on approach to antibody discovery. 

MALTS: 2 ROW, VIENNA, CRYSTAL DEXTROSE

HOPS: SIMCOE, CASCADE

YEAST: HOUSE YEAST

Six Pack mAbs Lager: A SUMMER SPECIAL
Abveris Beer Labels FINAL 2020-04-07 six pack mabs

Whether you’re catching the game, conquering the trail, or walking in the door from your commute home, sometimes you just need a beer. Brewed distinctively for the everyday, this classic American Lager is light and crisp, and will have you reaching for another sip. So kick your feet up, breathe easy, and crack into a can of this liquid bliss."

This beer label speaks for itself. We all love the beach this time of the year, and we love showing off the muscles we've built while sitting on our butts all day at the biosafety cabinets. 

MALTS: PILSNER, BOHEMIAN WHEAT

HOPS: MAGNUM, RAKAU

YEAST: LAGER YEAST

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

About Castle Island Brewery: 

Castle Island Brewery is based out of Norwood, Ma and can be found in fridges across New England. Their tasteful, easy to drink selection of beers is perfect for all beer drinkers from the beginner to the beer expert. Castle Island has their main staples, including the Keeper, American Lager, White Ale and CandlePin but they are always making new exciting beers to keep up with their loyal customers evolving tastes! Check out more on their website: www.castleislandbeer.com

Topics: Insider Events
2 min read

Abveris Announces Partnership with Nkarta using the Trianni Mouse on the Berkeley Lights Beacon

By Ryan Kelly on 5/12/20 8:08 AM

Click here to see the press release on BusinessWire.

Canton, MA, USA – Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Nkarta, Inc. (“Nkarta”) for the discovery of fully-human monoclonal antibodies to support the advancement of Nkarta’s novel cell-based therapeutics. Under the terms of the agreement, Abveris will apply its next-generation B cell screening platform (powered by the Berkeley Lights Beacon®) to rapidly discover fully human monoclonal antibodies using the Trianni Mouse®, an industry-leading transgenic mouse R&D platform. 

“We have worked with the Trianni Mouse across several therapeutic antibody programs and have been impressed with the success of these campaigns,” commented Colby Souders, Ph.D., Chief Scientific Officer of Abveris. “Abveris is uniquely positioned to dramatically shorten therapeutic discovery timelines while enhancing candidate selection by pairing optimized immunization methods in the Trianni Mouse with high-resolution single B cell screening enabled by the Berkeley Lights Beacon.”    

Trianni

“We believe this partnership brings together powerful discovery technologies with the potential for accelerating Nkarta’s pipeline of natural killer cell therapy candidates,” said James Trager, Ph.D., Chief Scientific Officer of Nkarta. “We look forward to working closely with the Abveris team on the identification of targeted antibodies ideally suited for our cell engineering and manufacturing platform.”

Learn more:  B cell screening at Abveris

“The Nkarta team is situated to redefine the way we think about cell therapies, and we are delighted to be working with their team of impassioned scientists,” added Tracey Mullen, MBA, Chief Operating Officer of Abveris. “This partnership highlights our continued commitment to working with organizations leveraging antibody therapeutics in innovative and transformative ways.” 

"We at Trianni are thrilled that the partnership of Abveris and Nkarta includes the use of the Trianni Mice. It is gratifying to contribute to the program of creating novel antibody therapeutics," said Matthias Wabl, Ph.D., Chief Executive Officer of Trianni, Inc.

Get in touch with Abveris

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

About Trianni, Inc: 

Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. Trianni’s lead technology, the Trianni Mouse®, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. Trianni’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology. The company is headquartered in San Francisco, CA. Additional information about Trianni is available through its corporate website, www.TRIANNI.com.

 

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

 

Contact for Trianni:

Elizabeth Tran

Marketing manager

elizabeth.tran@trianni.com

(415) 231-0257

 

Topics: Insider Press Releases
2 min read

Sustainable Science: Introducing Carbon-Neutral Shipping

By Matthew Bartolucci on 4/22/20 8:10 PM

Did you know that laboratory facilities often use 5-10x more energy compared to similarly-sized “normal” office spaces? Abveris is enacting sweeping changes to our laboratory and business operations to reduce our company's carbon footprint. 

In this post, we’ll detail our initiatives built to dramatically reduce the carbon cost of our shipping, including adopting carbon-neutral shipping methods and material reuse programs. We’ll share tips to implement similar changes at your company, too. 

 
Cold-chain shipping:
ESSENTIAL FOR RESEARCH & ENVIRONMENTALLY COSTLY 

Shipping is an important part of scientific collaborations today, which often extend beyond state and country lines. Since our founding five years ago, we’ve collaborated with scientists in more than 15 countries across four continents. For shipment of temperature-sensitive materials, we often rely on energy-intensive cold chain shipping methods that require additional packaging and refrigerants like ice packs, dry ice or liquid nitrogen. 

Initiative:
Carbon Offsets & Carbon-Neutral Shipping

Carbon offset programs allow small companies and individuals to participate in environmental projects to balance out their own carbon footprints. Abveris participates in verified carbon offset programs to support reforestation, landfill gas destruction, wastewater treatment, and methane destruction. 

You may be asking: how can I use carbon-neutral shipping?

Major shipping companies like UPS offer carbon-neutral shipping options. You'll be surprised to find that, often, the switch to carbon-neutral shipping will only impact shipment cost by $1 or less. 

Initiative:
Reduce, Reuse, Recycle

We are reducing our use of virgin materials by reusing the insulated shippers sent to us by our suppliers. We receive many high-quality insulated shipping containers used for the shipment of non-hazardous materials, like culture media.  Simply by reusing shipping boxes, we able to cut our use of virgin materials in half without sacrificing any quality of the materials we deliver to you.   

You may be asking: how can I start a box reuse program? 

Reusing a box should be easy in most BSL1 and BSL2 laboratory settings. Here are some quick tips to make sure you’re preparing the box appropriately to ship without issue:

  • Cover all outer box labels from the box's previous journey. 

    Cover all of the labels on the box, even those that might still be relevant. We recommend using blank white shipping labels to “white-out” and cover all of the stickers. Add the new box labels on top of the “white-out.”  This is important to ensure there are no delays in your shipment. 

  • When in doubt, throw it out.

    If the box is structurally compromised or potentially contaminated, it should not be reused. Only use boxes in good condition to keep your precious samples (and the people handling them) safe. 

  • For international shipments, it’s best to use new.

    During international shipping, it is best practice to present a tidy, clearly labeled product for customs agents. Additionally, for long distance shipments, it is important to select a container with well-defined limitations so you know how long the box will keep your samples cool. During long-distance journeys there may be limited opportunities for dry ice or ice pack replenishment. 

Topics: Green Initiatives
2 min read

FREE WEBINAR: High Throughput Antibody Discovery Targeting Cell Surface Receptors for Signaling Blocking in Cancer

By Travis LeGuyader on 4/14/20 3:11 PM

On-cell receptor functionality is a crucial threshold for drug development. By leveraging high content screening in antibody discovery workflows, you are able to improve the likelihood of campaign success at early stages of development. Join us for our webinar hosted by our COO Tracey Mullen and our friends at Sartorius, where Tracey will walk through a case study outlining how we incorporate this technology for antibody discovery projects targeting cell surface receptors. 

Tuesday, April 28, 2020, 11 am EDT

View on-demand webinar
 
Overview:

The use of monoclonal antibody-based therapeutics to target and treat cancer is considered to be one of the most successful therapeutic strategy within the oncology field to date. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution, early stage characterization of lead antibody drug candidates prior to preclinical development. In this webinar, Tracey Mullen, COO of Abveris, will review an antibody discovery campaign targeting a cell surface receptor implicated in cancer. Methods for immunization, antibody discovery, and subsequent functional characterization will be detailed.

Who Should Attend:
  • Antibody discovery scientists and researchers engaged in therapeutic drug discovery in oncology indications

  • Anyone interested in learning more about incorporating high-throughput flow cytometry analysis into early stage research and development

Speakers:
Tracey Mullen, Chief Operating Officer, Abveris

Tracey Mullen is a chemical-biological engineer from MIT who began her career as an Antibody Discovery Scientist at a startup contract research organization specializing in in vivo antibody discovery. In 2013, she joined the Antibody Discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to tough targets, including leveraging the Adimab platform to enerate antibodies against GPCRs. In June of 2018, Tracey joined Abveris Antibody as the Director of Antibody Discovery Operations, where she managed project design and development for in vivo discovery projects. She is now the Chief Operating Officer at AbX Biologics (formerly Abveris), a premium antibody discovery service partner boasting industry-leading timelines and cutting-edge technologies.

Carrie Haslam, Associate Editor, Select Science

Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Alzheimer’s disease and clinical diagnostics. She is finalizing her Ph.D. from Plymouth University, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.

View on-demand webinar

Topics: Insider Service & Product Updates Events
2 min read

Free Webinar: Accelerating the antibody discovery workflow in the modern therapeutic landscape

By Ryan Kelly on 4/9/20 9:15 AM

How can we access greater antibody diversity through the plasma B cell repertoire? How can we down-select lead candidates in 1 day? Join Abveris and Berkeley Lights for an exclusive webinar opportunity to learn how we're redefining the boundaries of antibody discovery with the Berkeley Lights Beacon platform.

Tuesday, April 14, 2020, 11 am EDT

View on-demand Webinar
 
Overview:

As the complexity of therapeutic targets continues to evolve, more efficient and predictive identification of pertinent antibody candidates becomes increasingly valuable. Incorporating state-of-the-art, high-resolution discovery and characterization tools like the Berkeley Lights platform into discovery workflows enables rapid and reliable selection of lead candidates more effectively than traditional techniques. Elucidating function early during screening and development can enhance candidate triage, as opposed to relying on brute-force methods to characterize large panels containing primarily non-functional clones. Optimization of the discovery platform using the Beacon instrument and case studies will be outlined.

Speakers:
Colby A. Souders, Ph.D., Chief Scientific Officer, Abveris

Colby holds a PhD in Cell and Molecular Biology from Texas A&M and has spent the last decade focused on antibody research. He first joined MassBiologics to lead discovery programs, develop platform technologies and advance monoclonal antibodies in the pipeline for the prevention, treatment or diagnosis of infectious and endogenous diseases. He later joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. In 2018 Colby joined Abveris Antibody with the goal as Chief Scientific Officer to usher in new antibody discovery tools and build a premium discovery engine.

Anupam Singhal, Ph.D., Product Manager, Antibody Therapeutics, Berkeley Lights

Anupam Singhal earned his PhD from the University of British Columbia and has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto and Stanford University. His work has been cited over 600 times and resulted in several patents for molecular disease diagnosis, antibody discovery, and development of production cell-lines for biologics. At Berkeley Lights, Anupam leads the development of next-generation platforms for the discovery and development of antibody therapeutics.

View on-demand Webinar

Topics: Insider Service & Product Updates Events
2 min read

Abveris and ACROBiosystems extend partnership

By Travis LeGuyader on 4/8/20 7:00 AM

Canton, MA, USA and Newark, DE, USA, April 8, 2020 - Abveris, Inc., a leader in contract research antibody discovery, today announced the extension of a strategic collaboration with ACROBiosystems, an internationally recognized manufacturer of recombinant proteins.

Under the terms of the agreement, the companies will leverage their core technologies to construct streamlined offerings to accelerate the pace of antibody discovery research.

Acro LogoBy the terms of the agreement, over 1600 recombinant proteins for biologic drug discovery and development available in the ACROBiosystems catalog will be made available to Abveris customers to facilitate rapid initiation of antibody discovery projects.

1600+ reagents at your fingertips click here to view the acro catalog

"Our collaboration with ACROBiosystems is a highly valuable resource for Abveris and all of our partner companies,” commented Ryan Kelly, Director of Business Development at Abveris. "Our access to ACRO’s high-quality “off-the-shelf” reagents allows us to identify diverse, high affinity antibody clones in as little as one month total.”

“We are delighted to collaborate with Abveris, who shows their expertise in therapeutic antibody development. Their special DiversimAbTM platform and single B cell screening platform speed up the antibody generation process while providing maximum diversity and affinity of the antibody candidates. It delivers additional benefits and comforts to scientists with using ACRO’s high-quality reagents and Abveris’s technologies as a combination,” commented Simin He, Marketing Manager of ACROBiosystems.

LET'S GET STARTED ON YOUR ANTIBODY PROJECT CLICK HERE TO INSTANTLY SET UP A CALL.

About Abveris: 

Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About ACROBiosystems: 

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process. Check out more details at: www.acrobiosystems.com/.

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

Contact for ACROBiosystems:

Grace Wang

Marketing Specialist

Grace.wang@acrobiosystems.com

408-320-2195

 

Topics: Insider Service & Product Updates
1 min read

Staying Open for Science, COVID Response

By Ryan Kelly on 3/20/20 12:44 PM

Abveris, Inc. 

March 18, 2020
RE: Staying Open for Science, COVID Response

 

To Our Valued Customers & Partners,

The COVID outbreak has caused significant disruptions to the science community worldwide, and your ongoing antibody discovery projects shouldn’t cause additional stress. Abveris will remain open for business and continue to provide contract research services during the state of emergency even if a "shelter-in-place" order is called. 

Abveris has multiple ongoing projects that directly contribute to drug development efforts for underserved diseases and indications (including COVID-19 and multiple other viral agents). Our end-to-end antibody discovery services are fully operational and we’re accepting new hybridoma and B cell screening discovery projects. Are you delaying your discovery work because of COVID-related antigen production delays? We can help.

Schedule 15 minutes with us today to discuss your project.

We are closely monitoring communications from the Massachusetts State and Federal Governments regarding measures to prevent the spread of the virus. Abveris has implemented mandatory work-from-home policies for non-essential staff, and employee schedules have been adjusted to promote social distancing. 

We welcome you to lean on us during these turbulent times. As always, we look forward to supporting your science.

 

Sincerely,

Garren Hilow

CEO of Abveris

 

Adversity has the effect of eliciting talents,

which in prosperous circumstances would have lain dormant

- Horace

Topics: Insider Press Releases Service & Product Updates
1 min read

Hey, Boston & Cambridge!  We're hosting a free happy hour!

By Travis LeGuyader on 2/12/20 7:30 AM

Updated 3/6/20: Event cancelled due to concerns surrounding spread of COVID-19 virus. 
A note from the event organizers:
Thank you for your interest in our event, and we apologize that we must postpone the happy hour indefinitely due to concerns surrounding the spread of Covid-19 infection. 
We're proud to announce that we had over 100 attendees registered a week ahead of the event. When the time is right, we will announce a revised event date. 

Thursday | March 12 | 5:00-7:30 PM | Cambridge, MA

Open Bar & Free Appetizers

What is Brews & Biopharma?

A free happy hour for biopharma scientists.

An exclusive, relaxed event for biopharma scientists in the protein sciences. Finish your workday (and start your night) with us over casual drinks, appetizers, and networking.

Who is invited?

Scientists from our partner companies and their invited guests*

*We kindly ask you not to invite your professional recruiter or salesperson friends as your guests. Nobody likes to be pitched after work. Thank you for respecting our policy. 

Topics: Insider Events
1 min read

Sustainable Science: Introduction to Our Green Initiatives Blog

By Matthew Bartolucci on 2/7/20 7:30 AM

 
Abveris is excited to announce our new Green Initiatives blog series.
Why are we “green-ing” our operations?


We are a group of biopharmaceutical scientists advancing a scientific mission to produce better biotherapeutic drugs. While our mission does not directly relate to environmental science, we recognize that environmental health ties directly to human health. Global climate scientists have reached a clear consensus: to address climate change, dramatic action must be taken now. To ignore our company’s contribution to global carbon emissions and climate change is irresponsible.

What’s the plan?

Abveris is enacting sweeping changes to our laboratory and business operations to reduce our company's carbon footprint. Did you know that laboratory facilities use 5-10x more energy compared to similarly-sized “normal” office spaces? As our lab continues to grow, we're scrutinizing our policies on energy use and sustainability so we can build valuable therapeutic products without leaving a harmful footprint.

Why are we blogging about it?

In this blog series, you’ll find information about our efforts to overhaul our company operations and move towards net carbon-neutrality. These initiatives extend beyond our laboratory and office to build support for eco-conscious behaviors at work, at home, and in our supply chain. By showcasing what we are doing in our labs and offices, we hope that other pharmaceutical scientists can follow our progress and enact changes in their own companies and institutions.

In each of our posts, we’ll break down the following:
  • What specific action are we taking to address climate change?
  • Why are we making a change?
  • What's the implementation strategy?
  • How do we expect to make an impact?
  • How can you, the reader, make a similar change in your own company?

Check out this blog series at abveris.com/greenscience to stay updated on our progress!

Topics: Green Initiatives
1 min read

WEBINAR: Integrating Octet into Early Antibody Discovery Workflows

By Ryan Kelly on 1/8/20 3:14 PM

Date: January 29, 2019 at 10AM ET (7AM PT)

Please join FortéBio and Abveris for an exclusive webinar featuring Colby Souders, Chief Scientific Officer of Abveris, who will review ways to utilize Octet screening to streamline antibody discovery projects.

View on demand Webinar

 

Who should attend:
  • Antibody discovery scientists and researchers engaged in therapeutic drug discovery.
  • Anyone interested in learning more about leveraging high-throughput Octet screening analyses to advance research and development.

Overview:

Integrating Octet into Early Antibody Discovery Workflows

Colby Souders, Chief Scientific Officer, Abveris

As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating instruments like the Octet into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. This presentation will highlight a few unique methods of Octet utilization as a replacement or supplemental tool for various antibody discovery protocols. Comparisons across platforms, including traditional ELISA, flow cytometry, SPR, and in vivo studies will be presented.

 

View on demand Webinar

Topics: Insider
1 min read

COO of Abveris, Tracey Mullen, to Present at Antibody Engineering 2019 in San Diego

By Travis LeGuyader on 12/3/19 1:49 PM

December 9, 2019 – San Diego, CA - Are you attending the upcoming Antibody Engineering and Therapeutics conference in San Diego on December 9th? It’s not too late to sign up and spend some time in the sun while staying updated on the latest antibody discovery technologies and engineering techniques while networking with lead scientists in the antibody discovery world.

Join us on December 12 at noon for a scientific briefing led by Tracey Mullen, our Chief Operating Officer. Or, stop by our booth or posters in the exhibit hall and meet with Garren (CEO), Ryan (Director of Business Development) and Travis (Business Development Associate). See you there!

Click here to schedule an appointment with our team at the conference.

 

Information on our Scientific Briefing:
Scientific Briefing: Antibody Discovery for Traditionally Difficult Targets: in vivo, in vitro, or both?

Abstract: Leveraging the natural immune repertoire for antibody discovery has distinct advantages for positive downstream outcomes, including efficacy, developability and safety; however, traditional techniques typically fail to produce a productive response in situations where, for example, the target epitope has poor immunogenicity or is a rare, cryptic site. While some in vitro platforms can overcome these difficulties through careful guiding selection methods, significant downstream engineering is often required to ensure lead candidates harbor appropriate development qualities. Fortunately, recent advancements in protein engineering and antibody discovery have enabled improved drug development to these traditionally difficult targets. Using the AbX platform, the power of the immune system is harnessed to exemplify the breadth and comprehensive nature of the B cell repertoire. When applied to the most difficult target classes, lead candidates can be uncovered where traditional in vivo platforms typically fail, or significant engineering is required for in vitro discovery.

About the Antibody Engineering Conference: Antibody Engineering is the #1 antibody engineering conference for accelerating next-generation antibodies to commercial success. Find the latest science, technology, and partners in antibody engineering, immunobiology, and next-generation binders.

 

Antibody Engineering Logo

 

Topics: Conferences
1 min read

Streamlining I-O Therapeutic Antibody Discovery: An Interview with Tracey Mullen, COO of Abveris

By Ryan Kelly on 12/3/19 7:34 AM

Insights from industry: Tracey Mullen, Chief Operating Officer of Abveris

Visit News Medical today to view an interview with Tracey Mullen, Chief Operating Officer of Abveris, in the "Insights from Industry" interview series.

In the interview, Tracey gives an overview of immuno-oncology therapeutic antibodies in development, strategies for therapeutic antibody discovery, and applications for the Intellicyt iQue high-throughput flow cytometry platform in antibody discovery.

For more information on antibody discovery projects utilizing high-throughput flow cytometry, contact Abveris today!

VIEW THE INTERVIEW

1 min read

WEBINAR: High-Throughput Antibody Discovery Targeting Glycoproteins for Apoptosis Induction in Cancer

By Ryan Kelly on 11/12/19 8:15 AM

Date: December 4, 2019 at 11AM ET (8AM PT)

IMG_1616Please join Sartorius and Abveris for an exclusive webinar featuring Tracey Mullen, Chief Operating Officer of Abveris, who will review an antibody discovery campaign targeting a glycoprotein for induction of apoptosis. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt® iQue platform will be detailed.

Who should attend:
  • Antibody discovery scientists and researchers engaged in therapeutic drug discovery for oncology indications.
  • Anyone interested in learning more about leveraging high-throughput flow cytometry analysis to advance research and development.
Interested, but have a scheduling conflict? Click here to register and receive an on-demand link to watch later.
About the webinar:

The use of monoclonal antibody-based drugs has proven very successful to target and treat cancer with more than half of late-stage clinical trial antibodies carrying an oncology indication. By employing multiple final formats, unconjugated or conjugated antibodies capitalize on methods of cell killing spanning from direct targeting and inhibition of cell survival pathways to shuttling and delivery of cytotoxic drugs. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution early stage characterization of lead antibody drug candidates prior to preclinical development.

Major advancements in high-throughput flow cytometry have enabled more exquisite antibody discovery within the oncology field by providing thorough analysis of on-cell antigen specificity and function earlier in the drug discovery process. In this webinar, an antibody discovery campaign targeting a glycoprotein for induction of apoptosis will be reviewed. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt iQue platform will be detailed.

Topics: Insider Service & Product Updates
1 min read

WEBINAR: Excellence In Anti-Idiotype Antibody Discovery

By Travis LeGuyader on 10/28/19 6:29 PM

Date: November 13, 2019 at 2PM ET (11AM PT)
TraceyMullenPlease join Abveris' Chief Operating Officer, Tracey Mullen, for our webinar to learn more about our premier anti-idiotype antibody discovery service for mAbs, bispecifics, scFvs, VHHs, and more.

Benefits of our approach:
  • Rapid reagent generation timelines
  • Maximal epitope coverage with DiversimAb technology
  • Highly sensitive specificity screening
  • Identification of high-affinity mAbs
  • Neutralizing and non-neutralizing mAbs
  • Flexible deliverable strategies
  • All work done in the USA

Abveris has the expertise and technology advantages required to develop high-quality reagents to the trickiest biotherapeutic molecules. Join our webinar to learn more.
Interested, but have a scheduling conflict? Click here to register and a video link will be sent after the webinar finishes. 

 

CLICK HERE TO DOWNLOAD OUR  ANTI-IDIOTYPE PRICING SHEET

 

CLICK HERE TO DOWNLOAD OUR  ANTI-IDIOTYPE PRICING SHEET

 

 

Topics: Insider Service & Product Updates

Now Hiring: Join Our Lab or Business Development Team

By Ryan Kelly on 10/19/19 1:59 PM

October 19, 2019 – Are you a team player looking for an exciting new challenge at a growing company? Visit our careers page today to learn about our open positions in our laboratory and business development teams.

Do you think you have the right attitude and the right experience to join our team, but the jobs we've posted don't look quite right for you? We welcome your application. Apply as an "antibody enthusiast" today!

Topics: Team Updates
1 min read

Meet the Team: Colby Souders

By Matthew Bartolucci on 10/8/19 7:08 AM

ColbySouders October 8, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Tune in to learn more about members of our team and see what they do inside and outside of work.

Colby Souders 
CSO
Q: What excites you about science?

A: We discover something new every day. Our purpose is to find something novel or better than its predecessor, and if we can do that, we improve many future lives. 

Q: What’s your favorite fun fact?

A: I am decidedly not a traveler (anyone who knows me would agree), yet I've been to three continents and lived in four different states. Go figure.  

Q: What do you do in your free time?

A: Spending time with friends and family.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: Every time someone learns or does something new, there's an overwhelmingly positive response. This is the best part of being at a growing company. 

Topics: Team Updates
1 min read

Abveris to attend Festival of Biologics 2019 in Basel, Switzerland

By Matthew Bartolucci on 10/3/19 10:17 PM

Basel, CH - October 4, 2019 - Will you be at the Festival of Biologics conference in Switzerland this year? Meet with our Director of Business Development, Ryan Kelly, who will be presenting a posters about our proprietary therapeutic antibody discovery technologies.  See you there from October 15-17.

About Festival of Biologics:

The Festival of Biologics combines four outstanding conferences, the European Antibody Congress, the World Immunotherapy Congress, the World Biosimilar Congress and the Clinical Trials World Congress to make one amazing event.

With both a conference and exhibition, the show brings together industry leaders to meet, discuss and showcase their work in the biologics, biopharma and immunotherapy fields, just to name a few.

The Congress hosts high-level speakers hailing from big pharma, biotech, academia, regulatory bodies, investor groups, and associations, discussing topics representing key challenges within their industries, new data, case studies and research.

This year, presentations will move through the entire development pipeline and focus on commercial applications. The Festival of Biologics’ mission is to bring together the full value chains from the antibodies, immunotherapy, clinical trials and biosimilars industries together, located in Basel – a major life science hub.

Topics: Conferences
1 min read

Meet the Team: Haley Wagner

By Madeleine Carbonneau on 10/1/19 8:09 AM

HaleyWagner October 1, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work.

Haley Wagner
Research Associate 
Q: What excites you about science?

A: I’m excited by how you can use science to help people and cure illnesses, the endless possibilities, the creativity aspect combined with the critical thinking aspect, understanding how things work, and discovering and learning new things constantly.

Q: What is your favorite fun fact?

A: Kindness is contagious.

Q: What do you do in your free time?

A: I like to cook, bake (and decorate), crafts and DIY, adventure with my chameleon, crossfit, run, hike, and explore state parks, blog, research/read about scientific topics and journal articles to improve my understanding and to be able to think of my own experiments, spend time with my Nana and Papa, guitar, hiking, biking, sell painted shells for charity, throw knives, and sew.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: It's really hard to choose just one. My favorite part of Abveris is working with such incredible people. I have a favorite memory with each person specifically, but my favorite memory as a group is the company party because I got to introduce my blood family to my work family. The coolest things I have done is a tie between getting the opportunity to attend and present at PEGS, getting to decorate the lab/office areas, when we troubleshoot and are able to get good sequence results from a difficult clone, and I'm extra excited about being able to contribute to develop ion channel antibodies.

Topics: Team Updates
1 min read

Meet the Team: Garren Hilow

By Matthew Bartolucci on 8/29/19 10:26 AM

GarrenHilow-1 August 29, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Tune in to learn more about members of our team and see what they do inside and outside of work.

Garren Hilow
CEO
Q: What excites you about science?

A: The direct application of biology to improve the health of people is very exciting and it's what we do here every day.

Q: Share a fun fact about you?

A: I once made extra money in college by selling balloon animals in the Downtown Crossing T station.

Q: What do you do in your free time?

A: I like to spend time with my wife and young son, mountain biking, and fishing.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: We have made a few antibodies that have gone on to be leads for our partners and have gone on to clinical trials. That direct application of our work to improving the health of our fellow humans is the coolest work I've done in my life.

Topics: Team Updates
1 min read

CSO of Abveris, Colby Souders, Ph.D., to Present at Discovery On Target 2019

By Ryan Kelly on 8/22/19 9:07 AM

August 22, 2019 – Boston, MA – Representatives from Abveris will attend the 17th Annual Discovery On Target Conference, September 16-19, 2019, in Boston, MA. Colby Souders, Chief Scientific Officer of Abveris, will serve as chairperson for the Antibody Engineering and Development Forum and present "Screening Tools for Early Prediction of Development and Clinical Success" at 3:40PM on Thursday, September 19. An abstract for the presentation is listed below.

Click here to schedule an appointment with the Abveris team during the conference.
Abstract:

As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating tools and methods into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. Comparisons across platforms, including traditional ELISA, flow cytometry, Octet and in vivo studies will be presented that provide enhanced prediction of downstream development and clinical success.

About Discovery On Target:

The 17th Annual Discovery on Target (DOT), the industry’s preeminent event on novel drug targets and technologies, will convene over 1,300 drug discovery professionals in Boston, MA, on September 16-19, 2019. This event highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.

Topics: Team Updates Conferences
1 min read

Abveris and Geneious Biologics Collaborate to Advance Antibody NGS Data Analysis

By Travis LeGuyader on 8/12/19 8:01 AM

Canton, MA, USA – August 12, 2019 – Boston-based antibody discovery services company Abveris has partnered with Biomatters to incorporate the Geneious Biologics data analysis platform into their antibody discovery workflow. In collaboration, a new Single Clone Antibody Annotator pipeline has been developed.

With a rapidly growing customer base and a wide range of antibody discovery services, Abveris plans to leverage the Geneious Biologics platform as a premium hub for bioinformatics and computer programming capabilities.

"The Geneious team has done an excellent job accommodating our specific data resulting in a streamlined, high-throughput workflow that produces accurate data and operates efficiently without the need to integrate multiple bioinformatics platforms," remarked Dr. Colby Souders, Chief Technology Officer at Abveris. "We look forward to continuously improving the platform and its integration into our workflow to combine sequence analytics with metadata and assay data to accelerate candidate selection."

The Geneious team worked closely with Abveris to optimize and enhance the handling of their antibody NGS data. Jannick Bendtsen, VP Technology Services at Geneious, commented, "Abveris is at the cutting edge of antibody drug discovery; they are pushing the boundaries of science and technology. To have Colby and the team select Geneious Biologics is a great honor and a great compliment. We collaborated to integrate our Single Clone Antibody Annotator Pipeline, and it now runs out of the box. It's all about speed and accuracy in the discovery process."

About Abveris: Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at https://www.abveris.com.

About Geneious and Biomatters: Biomatters empowers its customers with software that transforms biological data into knowledge and actionable insights across the spectrum of biotechnology research and development, including drug discovery, protein engineering, and advanced comparative analysis of DNA, RNA, and protein sequences. Geneious solutions are created from a deep understanding of customer experience to turn the difficult into the intuitive and easy. Geneious is trusted by over 4,000 companies, universities, and institutes all over the globe. Additional information about Geneious is available at https://www.geneious.com.

Topics: Press Releases Service & Product Updates
1 min read

Meet the Team: Jen Walker

By Madeleine Carbonneau on 8/6/19 10:30 AM

JenWalker August 6, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work.

Jen Walker 
Associate Director of Antibody Discovery Operations 
 
Q: What excites you about science?

A: Science helps us interrogate and understand our world, and by its very nature uncovers more questions with each answer. What could be cooler than that?!

 

Q: What is your favorite fun fact?

A: Honey bees must gather nectar from two million flowers to make one pound of honey.



Q: What do you do in your free time?

A: In my free time I spend time with my family and friends, work in my gardens, and volunteer as an advocate for individuals and families affected by Alzheimer's Disease.

 

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: I am very new to Abveris but it's already been a lot of fun! Here's a shout-out to the arrival of the Beacon, the barbeques, hibachi lunches and the on-going Corn Hole tournament (which has proved itself to be epic).

Topics: Team Updates
1 min read

Abveris and Lava Therapeutics Announce Antibody Discovery Collaboration

By Madeleine Carbonneau on 7/29/19 9:01 AM

Canton, MA, July 29, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced that it has entered into a collaborative agreement with Lava Therapeutics BV, a biopharmaceutical company developing next-generation T cell engager therapies. Under the terms of the agreement, Abveris will leverage its proprietary technology to develop critical reagent antibodies to support assay development for bispecific antibody γδ T cell engagers selected by Lava Therapeutics.

“The Abveris team is pleased to be working with Lava to accelerate the path to clinical development for their lead compound,” commented Ryan Kelly, Director of Business Development at Abveris. “We apply our proprietary hyperimmune platform to deliver consistent results for diverse biotherapeutic molecule formats. We look forward to working with the Lava Therapeutics team to help advance their γδ T cell engaging bispecific molecules.”

“We are delighted to enter a collaboration with Abveris on the generation of high-quality antibodies as critical reagents in our drug development programs of bispecific γδ T cell engagers. The use of the Abveris hyperimmune platform will enable the accelerated development of advanced (non-)clinical assays for our programs.” said Ton Adang, Senior VP and CDO of Lava Therapeutics B.V.

About Abveris:

Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About Lava Therapeutics:

Lava Therapeutics’ proprietary platform is focused on developing next-generation γδ T cell engaging bispecific antibodies to treat cancer. Lava’s vision is to develop therapeutics for the curative treatment of cancer. For more information, please visit www.lavatherapeutics.com.

 

Contact for Abveris:

Garren Hilow

contact@abverisantibody.com

+1 781-562-1170

Contact for Lava Therapeutics:

Erik Ensing

e.ensing@lavatherapeutics.com

Topics: Press Releases
1 min read

Meet the Team: Justin Gabriel

By Matthew Bartolucci on 7/24/19 10:30 AM

 


Justin Gabriel 

Research Associate - Lead TC

July 24, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work.JustinGabriel

 

Q: What excites you about science?

A: It never ends! I think the most fascinating aspect of science is the fact that we've been studying the world around us for so long and there's still an unfathomably immense amount of ground to cover.

 

Q: What is your favorite fun fact?

A: Under normal atmospheric pressure/conditions (on Earth), water molecules move from their liquid to gaseous phase at ~720 m/s!!!

 

Q: What do you do in your free time?

A: Everything! Racing drones, ride my motorcycle, work on my car, disc golf, going to the gym. I'd try almost anything once!

 

Q: What is the coolest thing you have done at Abveris/what is your favorite memory of working here?

A: I believe the"coolest" aspect of working here at Abveris is getting exposure to all different aspects of antibody production while getting the opportunity to work alongside some amazing people. I truly do love coming to work everyday and am very grateful for every opportunity this company has given me.

1 min read

Meet the Team: Ryan Kelly

By Matthew Bartolucci on 7/16/19 10:30 AM

RyanKelly July 16, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work.

Ryan Kelly

Director of Business Development

Q: What excites you about science?

A: Scientific understanding unlocks a whole new sensory experience that extends beyond vision, hearing, smell, taste, and touch.

Q: What is your favorite fun fact?

A: Polar bears don't actually have white fur. Also, they can run at 25 MPH.  Also, they are terrifying!

Q: What do you do in your free time?

A: During my free time, I'm often found in the mountains. I'm a fan of hiking (during any season!) and I'm a member of a ski club. Also, I have a huge, loving Boston Irish family, so there's a good chance you'll find me hanging out with them.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: During my time at Abveris, I've watched our team grow almost 10x in size. It has been an exciting adventure!  In my job, I get to interact directly with biopharma scientists from all over the globe. These relationships are what get me excited to get out of bed every morning.

1 min read

Meet the Team: Brendan Greamo

By Matthew Bartolucci on 7/12/19 11:04 AM

BrendanGreamo July 12, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work.

Brendan Greamo

Research Associate 

Q: What excites you about science?

A: I love understanding how things work, and watching this understanding be used to gain an even better grasp of how nature works. 

Q: What is your favorite fun fact?

A: Birds are dinosaurs.

Q: What do you do in your free time?

A: I like to feed my salamander and play basketball.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A:  The coolest thing I have done is to generate Abveris' largest ever batch of purified antibody... next stop:  1 gram!

Topics: Team Updates
3 min read

Meet the Team: Summer Interns

By Ryan Kelly on 7/9/19 10:30 AM

July 9, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work.

 

Matthew Bartolucci - Business Development Intern

MattBartolocci

 

Q: What excites you about science?

A: Science allows for all our our greatest questions to be answered. With the world always changing and evolving, our science is the way that we are able to adapt as a society and prepare for the world ahead.

Q: What is your favorite fun fact?

A: Garren, our CEO, and I have both play/played college ultimate frisbee for Bentley University's Icehouse

Q: What do you do in your free time?

A: Hanging out with friends, playing ultimate frisbee, slow-pitch softball and basketball!

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: I love the start-up culture! One minute, I am helping with our marketing tasks, and the next, I am helping others take out the garbage. Everyone pitches in and embraces the culture! 

 

Madeleine Carbonneau - Business Development Intern

 

MaddyCarbonneau

Q: What excites you about science?

A: There is still so much to discover! Every generation of scientists has the opportunity to make fantastic and revolutionary contributions.

Q: What is your favorite fun fact?

A: The national animal of Scotland is a unicorn.

Q: What do you do in your free time?

A: I like to run, drink coffee, and travel.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: The coolest thing I have done at Abveris is working on the back end of the website. It is really cool to see how different languages, programs, and software work together. Also, the people working at Abveris are all really great and committed to their work which makes working here all the more enjoyable.

 

Tadhg Daly - Lab Intern

 

TadhgDaley

Q: What excites you about science?

A: The pursuit of knowing more than I did yesterday

Q: What is your favorite fun fact?

A: Sloths can hold their breath longer than dolphins can.

Q: What do you do in your free time?

A: I like to collect retro video games and merchandise as well as play games with my friends.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: Assisting in protein purifications and being responsible for my own cell cultures for others to use in fusions

 

Kelly Rothenberger - Lab Intern

 

KellyRothenberger

Q: What excites you about science?

A: The possibility for discovering new concepts and that can help people in the future. Especially on the industry side, where creating exciting new things, (such as antibodies) can aid those who are using the new drug products to fight against different diseases. The exponential growth of the biotechnology industry is exciting and I cannot wait to see what I will be apart of in my future!

Q: What is your favorite fun fact?

A: When helium is cooled to almost absolute zero, it becomes a liquid, flowing against gravity and can start running up and over the lip of a glass container.

Q: What do you do in your free time?

A: I mostly enjoy to workout as often as I can, and I also horseback ride when possible.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: Watching my first fusion (done by Justin) on my 6th day of interning! I am so excited to make more memories!!

1 min read

Meet the Team: Tracey Mullen

By Madeleine Carbonneau on 7/5/19 10:43 AM

TraceyMullen July 5, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work.

Tracey Mullen
Chief Operating Officer

 

Q: What excites you about science?
A: The fact that the answer to most scientific questions is another question.

 

Q: Tell us a fun fact?

A: The hazelnut is actually not a nut, it's a seed.

Q: What do you do in your free time?

A: I like rock climbing and yoga (and hiking with a heavy backpack by default...crags tend to be far from civilization...)

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: PEGS Boston 2019! Seeing so many members of our team present and representing Abveris was truly inspiring.

Topics: Team Updates
2 min read

Abveris and Harbour Antibodies H2L2 BV Announce Technology Co-Offering Agreement for Fully Human Antibody Discovery

By Matthew Bartolucci on 7/1/19 8:01 AM

Click here to read the press release on Business Wire.

Canton, MA, USA, Cambridge, MA, USA, and Rotterdam, the Netherlands, July 1, 2019 - Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, today announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform. The combined offering eliminates the need for antibody humanization through the use of the H2L2 Harbour Mice™, and benefits from Abveris’ full suite of therapeutic antibody discovery capabilities.

Abveris was selected as a designated CRO to offer its fully-human antibody discovery service under the Co-Offering Agreement utilizing the H2L2 Harbour Mice™. The Co-Offering Agreement with Harbour includes a low-upfront evaluation fee and pre-negotiated commercial terms that Abveris can in turn provide to partners. The new Co-Offering allows Abveris clients to assess the H2L2 human transgenic mouse technology before committing to a full commercial license.

“We have historically generated potent, fully-human antibodies using the H2L2 Harbour Mice™. This program will allow us to continue to offer H2L2 antibody discovery with the elimination of contractual barriers for our biopharma partners seeking fully-human antibody discovery,” said Garren Hilow, CEO of Abveris. “We look forward to continuing our partnership with Harbour to use the H2L2 Harbour Mice™ in both our hybridoma platform and our AbX Biologics single B-cell discovery platform.”

“We are really excited about this Agreement which allows us to offer our partners access to this leading technology platform in the form of the H2L2 Harbour Mice™. It is an integral part of our strategy to build truly innovative products both in-house and with our partners, and the partnership with Abveris will further allow us to better fulfill unmet medical needs for patients worldwide,” said Jingsong Wang, MD, Ph.D., Chairman & CEO of Harbour BioMed.

Harbour’s patented H2L2 mouse platform provides antibody generation through a natural in vivo process, allowing for the generation of diversified, affinity matured, human antibody repertoires. Harbour Mice™ licensees include over 40 multinational pharmaceutical, biotechnology, and academic institutions. Abveris will leverage this platform in combination with its own proprietary immunization and high-throughput characterization capabilities to provide a fully-human therapeutic antibody discovery offering to its growing customer base.

 

About Abveris:

Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology and a variety of humanized mice. Additional information about Abveris is available at www.abveris.com

Contact:
Ryan Kelly, MBA
Abveris, Inc.
480 Neponset Street, Suite 10B
Canton, MA 02021, USA
contact@abverisantibody.com

About Harbour Antibodies:

Harbour Antibodies H2L2 BV is a fully owned subsidiary of Harbour BioMed, a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases (www.harbourbiomed.com). Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) mice that generate antibodies comprised of two heavy chains and two light chains (H2L2) with fully human variable regions; and (2) mice that generate novel “heavy chain only” antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable drug-like properties. For additional information, please visit www.harbourantibodies.com

Contact:
Jung Lee, Ph.D.
Harbour Antibodies
One Broadway
Cambridge, MA 02142, USA
Jung.Lee@harbourbiomed.com

Topics: Press Releases Service & Product Updates
1 min read

Meet the Team: Eric Batitay

By Matthew Bartolucci on 6/25/19 11:46 AM

EricBatitay June 25, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work

Eric Batitay
Senior Vivarium Manager
Q: What excites you about science?

A: The joy of discovery!

Q: What is your favorite fun fact?

A: Elephants think that humans are cute... and my wife thinks so, too!

Q: What do you do in your free time?

A: Spending time with my amazing family!

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: December 2017 is by far my best memory. It is when I started here at Abveris working with some of the greatest minds in the world.

Topics: Team Updates
1 min read

Meet the Team: Kate Teague

By Madeleine Carbonneau on 6/21/19 8:33 AM

KateTeague June 21, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Tune in to learn more about members of our team and see what they do inside and outside of work.

Kate Teague
Senior Manager, Business Operations
Q: What excites you about science?

A: I think it's cool that we've come so far in our understanding of the world around us, but there's still always more to discover and learn.

Q: What is your favorite fun fact?

A: A brown bear named Wojtek was officially drafted into the Polish army during WWII and rose to the rank of corporal. He aided his unit in the Battle of Monte Cassino by transporting 100-pound crates of artillery shells. He was also known to be an avid beer drinker.

Q: What do you do in your free time?

A: I enjoy cooking, reading, skiing, and going to the beach.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: I love planning our company outings and parties! We always have a great time and I feel so fortunate to work with such a great group of people. 

Topics: Team Updates
2 min read

Abveris Deploys the Berkeley Lights Beacon® Platform for Antibody Discovery

By Ryan Kelly on 6/17/19 7:48 AM

Click here to read the press release on Business Wire.

Canton, MA, June 17, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced the deployment of the Berkeley Lights, Inc. Beacon® optofluidic platform for antibody discovery.

Concurrent with this announcement, Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services. AbX Biologics will partner with biopharma companies to provide premium contract research capitalizing on a combination of proprietary in vivo technologies and the Beacon platform. The full AbX Biologics solution is expected to launch in 2020, with beta collaborations beginning Q3 2019. Abveris will continue to provide critical reagent antibody discovery and other antibody-related services.

“We are committed to integrating new and innovative technologies to our expanding suite of antibody discovery capabilities in an effort to continue providing premium services for our partners. We believe that the pioneering technology of the Beacon platform in combination with our own cutting-edge discovery expertise will enable us to deliver development-ready candidates in industry-leading timelines,” said Tracey Mullen, Chief Operating Officer of AbX Biologics and Abveris.

The Beacon platform provides accelerated single-cell screening and high-resolution analysis to identify and isolate antigen-specific antibody-secreting cells in a single day. AbX Biologics will leverage this groundbreaking technology in combination with its proprietary immunization and high-throughput characterization capabilities to provide a streamlined, best-in-class therapeutic antibody discovery offering to its growing customer base.

“We are delighted that Abveris and AbX Biologics have selected the Beacon Platform and our Antibody Discovery workflow for their therapeutic antibody discovery programs,” said Dr. Eric Hobbs, CEO of Berkeley Lights. “Berkeley Lights is driven to help companies accelerate the discovery of the best cells for their unique programs. We believe our work with AbX Biologics will help speed its antibody discovery efforts by screening more potential drug candidates faster, reducing the time from target to high value lead, and ultimately delivering new therapies to market faster.”

About Abveris:

Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAbTM hyperimmune mouse technology and a variety of humanized mice. Additional information about Abveris is available at www.abveris.com

About Berkeley Lights:

Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes workflows and processes for the biotechnology sector to accelerate the design, discovery, development, and delivery of cell-based products. By operating at the intersection of biology, technology and information, our workflows automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. BLI enables the rapid deployment of biology for the production of sustainable and scalable sources of food, therapies, and energy.

The Beacon platform is for Research Use Only. Not for use in diagnostic procedures.

Contact for Abveris:

Garren Hilow

contact@abverisantibody.com

781-562-1170

 

 

Topics: Press Releases Service & Product Updates
1 min read

Meet the Team: Chloe Emery

By Madeleine Carbonneau on 6/13/19 10:30 AM

ChloeEmery June 13, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Tune in to learn more about members of our team and see what they do inside and outside of work.


Chloe Emery
Senior Vivarium Manager
Q: What’s your favorite fun fact?

A: Did you know a rat can tread water for up to 3 days, and hold its breath underwater for 3 minutes?! That's how they can climb up your toilet.

Q: What excites you about science?

A: There are no mistakes in science, just temporary setbacks. Every misstep teaches you something that will help you succeed in the future.

Q: What do you do in your free time?

A: During the summer, I'm at the beach every waking moment that I'm not here at Abveris. In the colder months I'm at home knitting or painting. I'm also back in school for my Veterinary Nursing degree through Purdue's College of Veterinary Medicine, so that takes up a good chunk of time.

Q: What is your favorite memory of working at Abveris?

A: This is a really tough question! I feel like I do a lot of laughing here. Everyone is jokester, and they all enjoy taking a few moments out of their day to mess with each other. So I think all of my favorite memories are of pranks or someone jumping out to try and scare you. Or Brian singing about his chicken sandwich all day...

Topics: Team Updates
1 min read

Abveris to speak at the Future of Drug Discovery and Development Symposium

By Matthew Bartolucci on 6/11/19 10:35 AM

Boston, MA - June 11, 2019 - Ryan Kelly, the Associate Director of Business Development at Abveris, will give a talk about our advanced immunization strategies and antibody discovery platform technologies at the Future of Drug Discovery and Development Symposium hosted by ACROBiosystems and Biocytogen.

The symposium will be held on Thursday June 13, 2019 from 1-6PM in Cambridge.

Register for free to attend the symposium on Eventbrite.

Join the symposium to learn more about cutting-edge therapeutic antibody discovery technologies and the latest research in biologics drug development. The conference is free to attend, light refreshments and dinner will be provided.

Confirmed Speakers:

Chun-Nan Chen

CEO and CSO, Single Cell Technology

Qingcong Lin

CEO, Biocytogen Boston Corp

Stephen Gillies

CSO, LinkedUp Bioscience Inc

Johanna Lahdenranta

Director of In Vivo Pharmacology, Bicycle Therapeutics

Ryan Kelly

Associate Director, BD at Abveris, Co-Founder at AbX Biologics

Xiaodong Li

Associate of Patent and Intellectual Property, Choate, Hall & Stewart LLP

 

Click here to learn more about the symposium.

Event Details & Address:

Thursday June 13, 2019 from 1-6PM

Residence Inn Boston Cambridge

120 Broadway, Six Cambridge Center

Cambridge, MA

Topics: Conferences
1 min read

Abveris and TetraGenetics announce antibody discovery collaboration

By Ryan Kelly on 6/4/19 8:01 AM

Click here to read the press release on Business Wire.

Canton, MA, June 4, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced that it has entered into a multi-target agreement with TetraGenetics, Inc. a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders. Under the terms of the agreement, the companies will leverage their proprietary technologies to discover antibodies against traditionally difficult ion channel targets chosen by TetraGenetics.

"We are pleased to be working with TetraGenetics to develop antibodies against some of the most elusive therapeutic targets," commented Garren Hilow, CEO of Abveris. "The combined benefits of our proprietary hyperimmune platform along with TetraGenetics' unique ion channel technology provide a significant competitive advantage for discovery of antibodies against this traditionally difficult target class.

For the collaboration, the TetraGenetics’ TetraExpress platform will be leveraged in combination with the proprietary antibody discovery capabilities of Abveris for the discovery of diverse panels of antibodies with therapeutic potential.

“As our newest antibody partner, Abveris brings unique technology and a reputation for excellent execution to our growing list of drug discovery programs,” said Doug Kahn, CEO of TetraGenetics.

About Abveris:

Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About TetraGenetics:

TetraGenetics is focused on the discovery and development of first-in-class biologic medicines for autoimmune diseases, oncology and pain. The company has the leading drug discovery platform (TetraExpress™) for identifying antibodies targeting ion channels and other transmembrane proteins. TetraGenetics is actively building a proprietary drug pipeline and working collaboratively with major biotech companies for antibody drug discovery. For more information, please visit: www.tetragenetics.com.

 
Contact for Abveris:

Garren Hilow

contact@abverisantibody.com

781-562-1170

 

Contact for TetraGenetics:

Suzanne Gibbons-Neff

suzanne@sgnpr.com

203-858-1325

Topics: Press Releases
1 min read

Abveris to attend the PEGS Boston Protein Engineering Summit

By Ryan Kelly on 3/24/19 12:05 PM

Boston, MA - March 24, 2019 - Will you be at PEGS Boston this year? Come visit us in the exhibit hall at Booth #518. In addition to our exhibit, scientists from Abveris will be presenting two posters about our proprietary mouse technology and our anti-idiotype antibody discovery process.  See you there from April 8th - 12th.

About PEGS Boston:

PEGS: The Essential Protein Engineering Summit is the industry’s preeminent event that inspires innovative biotherapeutic protein drug development.

The PEGS Summit has celebrated record growth for ten consecutive years with over 2,600 industry professionals in attendance and is on track to set another new record this spring.

PEGS Boston 2019 will host more than 400 lectures, panels, tutorials and round-table discussions, along with 150+ exhibitors, and 300 research posters on display in the exhibit hall. The speaker lineup includes world-renowned experts, visionaries, and influencers from top pharma, biotech, academic, and government institutions.

Topics: Conferences
1 min read

Abveris announces formal launch of antigen production services

By Ryan Kelly on 2/20/19 8:55 AM

Canton, MA – February 20, 2019 – Abveris, Inc. today announced the addition of new capabilities to support antibody discovery campaigns. In-house antigen generation platforms have been established to support the production of plasmid DNA, recombinant proteins, and transfected cell lines for use in antibody discovery endeavors.

When reliable recombinant proteins are not available commercially, in house expi293- and expiCHO-based expression platforms are available for recombinant antigen production. We’ll build in confirmation testing checkpoints to ensure both parties are confident in the reagent before it is used for antibody discovery.

We generate transiently transfected cell lines in a bulk-transient cell line production procedure using our proprietary in-house vectors. With this method, we can rapidly deploy antibody discovery projects.

DNA immunization can be a strong approach for diverse target formats. We apply a suite of internal proprietary vectors to promote robust expression of your target directly in immunized mice.

Contact our team to learn more about antigen production services today.

Topics: Service & Product Updates
1 min read

Abveris appoints Tracey Mullen as Chief Operating Officer

By Ryan Kelly on 1/24/19 11:43 AM

Canton, MA – January 24, 2019 – Abveris, Inc. today announced that Director of Antibody Discovery Operations Tracey Mullen has been appointed Chief Operating Officer, a new position within Abveris. Mullen previously oversaw laboratory operations and will continue to report to Garren Hilow, CEO of Abveris.

“Tracey is an outstanding member of the Abveris team who consistently delivers results. Her promotion to Chief Operating Officer is in recognition of the consistency and accountability she has demonstrated as Director of Operations,” said Garren Hilow, CEO. “I have tremendous confidence in Tracey’s ability to drive the future of innovation at Abveris with her laser-focus on operational excellence.”

An MIT graduate, Mullen joined Abveris in 2018 after five years of scientific employ at Biogen. During her time at Biogen, Mullen was engaged in biotherapeutics discovery work using diverse platform technologies.

In her free time, Mullen is an avid rock climber who can be found traveling to the most distant regions of the country with her husband and Siberian husky in search of exciting climbing routes.

Topics: Team Updates

Featured